Skip to main content

Lung ultrasound score and in-hospital mortality of adults with acute respiratory distress syndrome: a meta-analysis

Abstract

Background

Lung ultrasound (LUS) score could quantitatively reflect the lung aeration, which has been well applied in critically ill patients. The aim of the systematic review and meta-analysis was to evaluate the association between LUS score at admission and the risk of in-hospital mortality of adults with acute respiratory distress syndrome (ARDS).

Methods

Toachieve the objective of this meta-analysis, we conducted a thorough search of PubMed, Embase, Cochrane Library, and the Web of Science to identify relevant observational studies with longitudinal follow-up. We employed random-effects models to combine the outcomes, considering the potential influence of heterogeneity.

Results

Thirteen cohort studies with 1,022 hospitalized patients with ARDS were included. Among them, 343 patients (33.6%) died during hospitalization. The pooled results suggested that the LUS score at admission was higher in non-survivors as compared to survivors (standardized mean difference = 0.73, 95% confidence interval [CI]: 0.55 to 0.91, p < 0.001; I2 = 25%). Moreover, a high LUS score at admission was associated with a higher risk of in-hospital mortality of patients with ARDS (risk ratio: 1.44, 95% CI: 1.14 to 1.81, p = 0.002; I2 = 46%). Subgroup analyses showed consistent results in studies with LUS score analyzed with 12 or 16 lung regions, and in studies reporting mortality during ICU or within 1-month hospitalization.

Conclusion

Our findings suggest that a high LUS score at admission may be associated with a high risk of in-hospital mortality of patients with ARDS.

Peer Review reports

Introduction

Acute respiratory distress syndrome (ARDS) is a severe pathological state characterized by refractory hypoxemia resulting from diverse etiological factors, commonly arising as a secondary manifestation of pulmonary disorders or extrapulmonary conditions, including pneumonia, drowning, and non-pulmonary sepsis [1,2,3]. Clinically, ARDS has been associated with a multitude of detrimental outcomes, encompassing respiratory failure, critical illness, and fatality [4]. Among patients admitted to the intensive care unit (ICU), the incidence of ARDS has been estimated to approximate 10% [5]. Despite advancements in intensive care over the past few decades, ARDS remains an underrecognized, deleterious, and potentially fatal ailment, with mortality rates reaching as high as 50% [6]. Consequently, it is imperative to ascertain the risk factors associated with immediate mortality in individuals afflicted with ARDS.

Lung ultrasound (LUS) has emerged as a valuable and non-invasive modality for promptly assessing chest conditions in individuals with respiratory disorders, particularly in acute scenarios like emergency department and ICU settings [7, 8]. The growing body of evidence indicates that LUS offers several advantages, including cost-effectiveness, expeditiousness, absence of ionizing radiation, bedside accessibility, and method repeatability [9, 10]. In patients with ARDS, the evaluation of lung aeration can be accomplished by monitoring alterations in the appearance of A-lines and B-lines across various lung regions, and quantitatively evaluated as the LUS score [11]. A recent comprehensive study has substantiated the precision of the LUS aeration score in diagnosing ARDS [12, 13]. Nevertheless, preliminary studies have yielded incongruous findings concerning the correlation between the LUS score upon admission and the likelihood of in-hospital mortality among adult patients with ARDS [14,15,16,17,18,19,20,21,22,23,24,25,26]. Given this prevailing uncertainty, we conducted a systematic review and meta-analysis to consolidate the present comprehension of the prognostic significance of the LUS score upon admission for ARDS.

Materials and methods

Throughout the process of planning, conducting, and reporting the study, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement [27, 28] and Cochrane Handbook [29] were followed.

Inclusion and exclusion criteria of studies

Inclusion criteria were developed per PICOS recommendations and according to the aim of the meta-analysis.

P (patients): Hospitalized adult patients (18 years or older) with a confirmed diagnosis of ARDS, which was diagnosed in accordance with the Berlin Definition [1].

I (exposure): LUS score was measured at admission. Methods for measuring LUS score were consistent with the protocols used among the included studies, which generally included the protocols of 12-region method (0 ~ 36 points of score) and a 16-region method (0 ~ 48 points) [30, 31]. Patients with a high LUS score at admission were considered as exposure, and the cutoff for defining high LUS score was also according to the cutoff used among the original studies.

C (control): Patients with a low LUS score at admission.

O (outcomes): Incidence in all-cause mortality during hospitalization was observed. The primary outcome was to compare the difference of LUS score at baseline between non-survivors and survivors of hospitalized patients with ARDS. The secondary outcome was to compare the incidence of in-hospital mortality between hospitalized ARDS patients with high versus low LUS score at admission.

S (study design): Studies with longitudinal follow-up, including cohort and nested case-control studies, and post-hoc analyses of clinical trials. Excluded from the meta-analysis were reviews, editorials, preclinical studies, and studies that did not involve patients with ARDS, studies including neonates or children, studies did not measure LUS score at baseline, or studies did not report the outcome of in-hospital mortality. In instances with a patient population overlap, the study with the greatest sample size was incorporated into the meta-analysis.

Search of databases

We searched electronic databases, including PubMed, Embase, Cochrane Library, and Web of Science, starting from inception and ending July 21, 2023, for studies that had been published up to that date. The search was performed with terms related to our study, including (1) “ultrasonography” OR “ultrasound” OR “ultrasonic” OR “ultrasonographic”; (2) “lung” OR “pulmonary”; (3) “score” OR “scores”; and (4) “acute respiratory distress syndrome” OR “respiratory distress syndrome” OR “ARDS”. Only studies published as full-length articles in English or Chinese peer-reviewed journals were considered. As part of our manual screening process, references from relevant original and review articles were screened for possible relevant studies.

Data extraction and quality evaluation

Two authors independently conducted comprehensive literature searches, collected data, and assessed the quality of the included studies. In cases where discrepancies arose, discussions between the two authors were indicated until a consensus was achieved. The analysis of the studies involved the extraction of relevant information, such as study details, design characteristics, patient diagnoses, demographic factors, methods and timing for LUS examination, follow-up duration, number of patients that died during hospitalization, outcomes reported, and the variables matched or adjusted for evaluating the association between LUS score and in-hospital mortality of patients with ARDS. To evaluate the quality of the included studies, we utilized the Newcastle–Ottawa Scale (NOS) [32], which assesses participant selection, comparability of the study groups, and the validity of the outcomes. The NOS scoring system comprises nine stars, with more stars indicating a higher quality study.

Statistics

Standardized mean differences (SMD) and corresponding 95% confidence interval (CI) were used to present the potential difference of LUS score at admission between the non-survivors and survivors of patients with ARDS. Risk ratios (RR) and corresponding 95% CI were used as the variables to indicate the association between LUS score and the risk of in-hospital mortality among patients with ARDS. A logarithmical transformation was performed on the RR and its corresponding standard error from each study to stabilize and normalize its variance [33]. In order to estimate between-study heterogeneity, the Cochrane Q test and the I2 statistic [34] were used. An I2 > 50% indicates that there is significant heterogeneity between studies. A random-effects model was employed to amalgamate the findings, as it has been acknowledged to encompass the impact of potential heterogeneity [29]. Sensitivity analysis by excluding one study at a time was performed to evaluate the influence of individual study on the results of the meta-analyses. Subgroup analyses were also performed to evaluate the potential influence of study characteristics on the results, such as study design, methods and cutoffs for evaluating LUS score, and follow-up durations. A funnel plot and Egger’s regression asymmetry test were used to estimate publication bias based on visual symmetry judgments [35]. The statistical analyses were done with RevMan (Version 5.1; Cochrane Collaboration, Oxford, UK) and Stata software (version 12.0; Stata Corporation, College Station, TX).

Results

Database search and study retrieval

Figure 1 illustrates the step-by-step process of the literature search and study retrieval. Initially, a total of 642 records were identified from the databases. After removing 159 duplicate entries, 483 unique records remained. Subsequently, 457 studies were excluded during the initial screening of titles and abstracts as they did not align with the objectives of the meta-analysis. After this initial screening, 26 studies were selected for further assessment through full-text reviews. Following the rigorous review process, 13 studies were excluded for specific reasons detailed in Fig. 1. Consequently, 13 cohort studies were deemed suitable and were included in the subsequent meta-analysis [14,15,16,17,18,19,20,21,22,23,24,25,26].

Fig. 1
figure 1

Flowchart of database search and study inclusion

Study characteristics

Overall, 13 cohort studies, including eight prospective studies [15, 17, 19, 20, 22,23,24, 26] and five retrospective studies [14, 16, 18, 21, 25], were analyzed in this meta-analysis. The characteristics of the included studies are summarized in Table 1. These studies were performed in China, India, and Italy, and published between 2014 and 2023. A total of 1,022 hospitalized adult patients with ARDS were included. The etiologies of ARDS varied among the included studies, with four studies included patients with ARDS related to infection [14, 17, 21, 23]. The mean ages of the patients were 51 to 78 years, and the proportions of men were 43 to 83%. For all the included studies, LUS was performed within 24 h after admission, with the 12-region method used in ten studies [15, 16, 19,20,21,22,23,24,25,26], and the 16-region method in three studies [14, 17, 18]. The follow-up duration was during ICU in six studies [15, 16, 21,22,23, 25], and was 28 or 30 days in seven studies [14, 17,18,19,20, 24, 26]. Among the included patients, 343 patients (33.6%) died during hospitalization. The difference of LUS score at baseline between non-survivors and survivors were reported in 11 studies [14,15,16,17, 19,20,21, 23,24,25,26], and RR of in-hospital mortality between patients with high versus low LUS score were reported in six studies [18, 20, 22, 23, 25, 26]. Median of LUS score was selected as the cutoff value in four studies [18, 20, 22, 23], while the receiver operating characteristic (ROC) analysis derived cutoff value was used in the other two studies [25, 26]. Univariate analysis was used to determine the association between LUS score and in-hospital mortality in two studies [14, 18], age was controlled in the remaining 11 studies [15,16,17, 19,20,21,22,23,24,25,26], with nine of them also controlled for other confounding factors [15, 19,20,21,22,23,24,25,26]. The NOS of the included studies were 6 to 9, indicating that they were of moderate to good quality (Table 2).

Table 1 Characteristics of the included studies
Table 2 Study quality evaluation via the Newcastle-Ottawa Scale

Difference of LUS score between non-survivors and survivors

Pooled results with 11 studies [14,15,16,17, 19,20,21, 23,24,25,26] showed that compared to survivors during hospitalization, patients with ARDS who died during hospitalization had a significant higher LUS score at admission (SMD = 0.73, 95% CI: 0.55 to 0.91, p < 0.001; Fig. 2A) with mild heterogeneity (I2 = 25%). Sensitivity analysis by excluding one study at a time showed consistent results (SMD: 0.69 to 0.76, p all < 0.05). Specifically, sensitivity analysis limited to studies of patients with infectious etiologies of ARDS showed similar results (SMD = 0.71, 95% CI: 0.31 to 1.12, p < 0.001; I2 = 27%). Further subgroup analyses showed consistent results in prospective and retrospective studies (p for subgroup difference = 0.73, Fig. 2B), in studies of LUS score analyzed with 12-region or 16-region method (p for subgroup difference = 0.16, Fig. 3A), and in studies reporting mortality during ICU or within 1-month hospitalization (p for subgroup difference = 0.55, Fig. 3B).

Fig. 2
figure 2

Forest plots for the meta-analysis of the difference of LUS score at admission between non-survivors and survivors of ARDS patients; (A), overall meta-analysis; and (B), subgroup analysis according to study design

Fig. 3
figure 3

Forest plots for the meta-analysis of the difference of LUS score at admission between non-survivors and survivors of ARDS patients; (A), subgroup analysis according to methods for evaluating LUS score; and (B), subgroup analysis according to follow-up durations

RR for the association between LUS score and in-hospital mortality

Meta-analysis of six studies [18, 20, 22, 23, 25, 26] showed that a high LUS score at admission was associated with a higher risk of in-hospital mortality of patients with ARDS (RR: 1.44, 95% CI: 1.14 to 1.81, p = 0.002; Fig. 4A) with moderate heterogeneity (I2 = 46%). Sensitivity analysis by excluding one study at a time showed consistent results (RR: 1.33 to 1.55, p all < 0.05). In addition, subgroup analysis showed that the association may be stronger in retrospective studies as compared to prospective studies (RR: 2.34 versus 1.26, p = 0.01; Fig. 4B), which fully explained the source of heterogeneity. Moreover, subgroup analyses showed similar results in studies of LUS score analyzed with 12-region or 16-region method (p for subgroup difference = 0.09, Fig. 4C), in studies using median or ROC derived cutoffs for LUS score (p for subgroup difference = 0.09, Fig. 5A), and in studies reporting mortality during ICU or within 1-month hospitalization (p for subgroup difference = 0.36, Fig. 5B).

Fig. 4
figure 4

Forest plots for the meta-analysis of the association between LUS score at admission and in-hospital mortality of patients with ARDS; (A), overall meta-analysis; (B), subgroup analysis according to study design; and (C), subgroup analysis according to methods for evaluating LUS score

Fig. 5
figure 5

Forest plots for the meta-analysis of the association between LUS score at admission and in-hospital mortality of patients with ARDS; (A), subgroup analysis according to the cutoff of LUS score; and (B), subgroup analysis according to follow-up durations

Publication bias

The funnel plots for the meta-analyses of the difference of LUS scores between non-survivors and survivors and RR for the association between LUS scores and in-hospital mortality of patients with ARDS are shown in Fig. 6A and B. Based on visual examination, the plots are symmetrical, suggesting low publication biases. Additionally, Egger’s regression tests indicated a low likelihood of publication biases (p = 0.81 and 0.29).

Fig. 6
figure 6

Funnel plots for the publication biases underlying the meta-analyses; (A), funnel plots for the meta-analysis of the difference of LUS score at admission between non-survivors and survivors of ARDS patients; and (B), funnel plots for the meta-analysis of the association between LUS score at admission and in-hospital mortality of patients with ARDS

Discussion

This systematic review and meta-analysis integrated the results of 13 cohort studies and showed that a high LUS score at admission may be associated with an increased risk of in-hospital mortality of adult patients with ARDS. Subsequent sensitivity analysis showed consistent results by excluding one study at a time, and in studies of patients with ARDS with the etiology of infection. Moreover, subgroup analysis showed similar results in prospective and retrospective studies, in studies of different methods and cutoff values for evaluating LUS scores, and in studies of different follow-up durations. Taken together, results of the meta-analysis suggested that a high LUS score at admission may be a predictor of in-hospital mortality of adult patients with ARDS.

To the best of knowledge, no meta-analysis has been published regarding the association between LUS score at admission and the in-hospital mortality in patients with ARDS. Ultrasound possesses numerous advantages, including its sterilization convenience, affordability, and lack of radiation [7]. In recent times, LUS has emerged as a precise diagnostic instrument for respiratory ailments [36]. Particularly for patients afflicted with critical conditions like ARDS, LUS can be conducted at the patient’s bedside, thereby mitigating the hazards associated with patient transportation [36]. Furthermore, LUS allows for repetitive examinations, rendering it an exceptional monitoring tool. A sonographer administers the designated LUS protocol and subsequently calculates the LUS score, which is determined by summing the scores assigned to each lung region examined through the measurements of lung aeration loss [37]. Although the protocol of LUS score measurement may be varied, which mainly include the 8-region (0 ~ 24 points), 12-region (0 ~ 36 points), and 16-region (0 ~ 48 points) methods, it has been suggested that the efficacy of these protocols may be similar [38, 39]. Our subgroup results according to the different protocols of LUS score measuring methods also showed consistent results. The mechanisms underlying the association between a high LUS and increased risk of in-hospital mortality of patients with ARDS may be multifactorial. In general, a higher LUS score is indicative of a more severe distribution of extravascular lung water, which indirectly hinders the oxygenation of blood [16]. Furthermore, a higher LUS score in patients diagnosed with ARDS has been found to be correlated with various clinical variables that are associated with a poor prognosis, such as the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2), serum lactate acid levels, and Sequential Organ-Failure Assessment score [18]. Another study conducted on patients with ARDS demonstrated that the LUS score measured at the conclusion of a 60-minute spontaneous breathing trial could serve as a predictor of post-extubation distress, suggesting that a higher LUS score may also be linked to delayed extubation [40]. Furthermore, a recent study has demonstrated a significant correlation between a higher LUS score and patient-reported dyspnea at rest and exertion in individuals who have survived ARDS following their stay in the ICU. These findings imply that, in addition to its ability to predict short-term prognosis, the LUS score may serve as an indicator of the long-term functional status of ARDS patients [41]. From a clinical perspective, results of the meta-analysis support an important role of LUS score for the prognostic evaluation of patients with ARDS. A high LUS score at admission may suggest a worse pulmonary status, which requires timely intensive evaluation with other possible biochemical and imaging examinations, and also an intensive respiratory support. However, further research is required to ascertain the precise role of the LUS score in the management of individuals with ARDS.

The strengths of the meta-analysis include extensive literature search in four databases, performing two independent meta-analyses to confirm the association between LUS score and in-hospital mortality of ARDS, and conducting multiple sensitivity and subgroup analysis to validate the robustness of the findings. However, this study is subject to certain limitations. First, 11 of the included 13 studies were performed in China, and results of the meta-analysis should better be confirmed in large-scale prospective studies from other countries. Second, the optimal protocol and cutoff value for determining the high LUS score at admission in patients with ARDS remain to be determined. In addition, LUS evaluation for ARDS is based on a scoring system according to the regionally presentation of well separated B lines (1 point), coalescent B lines (2 points), and lung consolidation (3 points) [42]. It has to be mentioned that B lines are the product of an artifact of ultrasonic beam reverberation against interfaces of different consistency [43]. Although B lines may be generally caused by extravascular lung water in patients with ARDS, identifying the varying pathophysiological conditions (such as fibrosis) that result in subtle differences in B line appearance is impossible based on LUS alone [43]. Moreover, although multivariate analyses were performed in some of the included studies when the association between LUS and in-hospital mortality was determined, we could not exclude the possibility that there are some other clinical factors that may confound this association. For example, ARDS is a multisystem disease which may involve the dysfunction of other organs besides the lung, and the severity of dysfunctions of these organs could affect the mortality of the patients. Studies are needed in the future to determine if the association between LUS score at admission and the mortality of patients with ARDS is consistent in patients with and without multi-organ dysfunction. Finally, it remains unknown whether incorporating LUS score could improve the predictive efficacy of current prognostic evaluation models for patients with ARDS.

Conclusions

In conclusion, results of our findings suggest that a high LUS score at admission may be associated with a high risk of in-hospital mortality of patients with ARDS. In view of the multiple advantages of LUS for critically ill patients such as cost-effectiveness, expeditiousness, and bedside accessibility, these findings support the use of LUS score for the severity evaluation and mortality prediction in patients with ARDS.

Data availability

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

References

  1. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526–33.

    PubMed  Google Scholar 

  2. Gorman EA, O’Kane CM, McAuley DF. Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management. Lancet. 2022;400(10358):1157–70.

    Article  PubMed  Google Scholar 

  3. Bos LDJ, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. Lancet. 2022;400(10358):1145–56.

    Article  PubMed  Google Scholar 

  4. Ramji HF, Hafiz M, Altaq HH, Hussain ST, Chaudry F. Acute respiratory distress syndrome; a review of recent updates and a glance into the future. Diagnostics (Basel) 2023, 13(9).

  5. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, et al. Epidemiology, patterns of Care, and mortality for patients with Acute Respiratory Distress Syndrome in Intensive Care Units in 50 countries. JAMA. 2016;315(8):788–800.

    Article  CAS  PubMed  Google Scholar 

  6. Grotberg JC, Reynolds D, Kraft BD. Management of severe acute respiratory distress syndrome: a primer. Crit Care. 2023;27(1):289.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mojoli F, Bouhemad B, Mongodi S, Lichtenstein D. Lung ultrasound for critically Ill patients. Am J Respir Crit Care Med. 2019;199(6):701–14.

    Article  PubMed  Google Scholar 

  8. Rocca E, Zanza C, Longhitano Y, Piccolella F, Romenskaya T, Racca F, Savioli G, Saviano A, Piccioni A, Mongodi S. Lung ultrasound in critical care and Emergency Medicine: clinical review. Adv Respir Med. 2023;91(3):203–23.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Cammarota G, Vetrugno L, Longhini F. Lung ultrasound monitoring: impact on economics and outcomes. Curr Opin Anaesthesiol. 2023;36(2):234–9.

    Article  PubMed  Google Scholar 

  10. Arbelot C, Ferrari F, Bouhemad B, Rouby JJ. Lung ultrasound in acute respiratory distress syndrome and acute lung injury. Curr Opin Crit Care. 2008;14(1):70–4.

    Article  PubMed  Google Scholar 

  11. Chiumello D, Mongodi S, Algieri I, Vergani GL, Orlando A, Via G, Crimella F, Cressoni M, Mojoli F. Assessment of Lung Aeration and Recruitment by CT scan and Ultrasound in Acute Respiratory Distress Syndrome patients. Crit Care Med. 2018;46(11):1761–8.

    Article  PubMed  Google Scholar 

  12. Smit MR, Hagens LA, Heijnen NFL, Pisani L, Cherpanath TGV, Dongelmans DA, de Grooth HS, Pierrakos C, Tuinman PR, Zimatore C, et al. Lung Ultrasound Prediction Model for Acute Respiratory Distress Syndrome: a Multicenter prospective observational study. Am J Respir Crit Care Med. 2023;207(12):1591–601.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Corradi F, Brusasco C, Pelosi P. Chest ultrasound in acute respiratory distress syndrome. Curr Opin Crit Care. 2014;20(1):98–103.

    Article  PubMed  Google Scholar 

  14. Ding X, Liu D, Wang X, Wang C, Zhang H, Liu Y, Chen H, Tang B, Du W. The value of prone position lung ultrasound examination in predicting the prognosis of Acute Respiratory Distress Syndrome receiving prone ventilation. Chin J Intern Med. 2014;53(9):719–23.

    Google Scholar 

  15. Li L, Yang Q, Guan J, Liu Z, Han J, Chao Y, Wang Z, Yu X. The value of lung ultrasound score on evaluating clinical severity and prognosis in patients with acute respiratory distress syndrome. Chin Crit Care Med. 2015;27(7):579–84.

    Google Scholar 

  16. Zhao Z, Jiang L, Xi X, Jiang Q, Zhu B, Wang M, Xing J, Zhang D. Prognostic value of extravascular lung water assessed with lung ultrasound score by chest sonography in patients with acute respiratory distress syndrome. BMC Pulm Med. 2015;15:98.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Wang XT, Ding X, Zhang HM, Chen H, Su LX, Liu DW. Lung ultrasound can be used to predict the potential of prone positioning and assess prognosis in patients with acute respiratory distress syndrome. Crit Care. 2016;20(1):385.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lv W, Wang S, Wang L, Wu Z, Jiang Y, Chen X, Gao R. G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene and lung ultrasound score as prognostic markers in evaluating the outcome of acute respiratory distress syndrome. Exp Ther Med. 2019;17(4):3174–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Xie Y, Qian Y, Liu K, Liu S, Zheng H, Cao L, Li X. Correlation analysis between mechanical power and lung ultrasound score and their evaluation of prognosis in patients with acute respiratory distress syndrome. Chin Crit Care Med. 2019;31(6):704–8.

    Google Scholar 

  20. Yu Y, Liu Z, Liao H, He Y, Li C. The value of serum microRNA-92a and microRNA-146a levels combined with pulmonary ultrasound score in predicting the severity and prognosis of acute respiratory distress syndrome. Chin Crit Care Med. 2020;32(10):1231–5.

    Google Scholar 

  21. Zhang L, Yu W, Zhou C, Chen G. Application of lung ultrasonography on evaluating extravascular lung water and prognosis in patients with acute respiratory distress syndrome. Chin Crit Care Med. 2020;32(5):585–9.

    Google Scholar 

  22. Chaudhuri S, Maddani SS, Rao S, Gauni S, Arjun NR, Todur P, Gupta N. Correlation of serum albumin level to Lung Ultrasound score and its role as predictors of Outcome in Acute Respiratory Distress Syndrome patients: a prospective observational study. Crit Care Res Pract. 2021;2021:4594790.

    PubMed  PubMed Central  Google Scholar 

  23. Lazzeri C, Bonizzoli M, Batacchi S, Socci F, Matucci-Cerinic M, Peris A. Combined lung and cardiac ultrasound in COVID-related acute respiratory distress syndrome. Intern Emerg Med. 2021;16(7):1779–85.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Xie Y, Liu S, Mou Z, Wang Y, Li X. Correlation analysis between Mechanical Power and Lung Ultrasound score and their evaluation of severity and prognosis in ARDS patients. Biomed Res Int. 2021;2021:4156162.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Guo C, Chu Y, Fu H. Correlation between dead space fraction and pulmonary ultrasound score in patients with acute respiratory distress syndrome and its prognostic value. Chin Crit Care Med. 2022;34(5):514–8.

    Google Scholar 

  26. Zheng QM, He YL, Li XD, Xu XL, Fu CH. Correlation between serum autotaxin level and pulmonary ultrasound score with the Disease severity and 28-day mortality in patients with acute Respiratory Disease syndrome. Chin J Tuberc Respir Dis. 2023;46(1):40–5.

    CAS  Google Scholar 

  27. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V. Cochrane Handbook for systematic reviews of interventions version 6.2. The Cochrane Collaboration; 2021. www.training.cochrane.org/handbook.

  30. Soummer A, Perbet S, Brisson H, Arbelot C, Constantin JM, Lu Q, Rouby JJ. Ultrasound assessment of lung aeration loss during a successful weaning trial predicts postextubation distress*. Crit Care Med. 2012;40(7):2064–72.

    Article  PubMed  Google Scholar 

  31. Gil-Rodriguez J, Perez de Rojas J, Aranda-Laserna P, Benavente-Fernandez A, Martos-Ruiz M, Peregrina-Rivas JA, Guirao-Arrabal E. Ultrasound findings of lung ultrasonography in COVID-19: a systematic review. Eur J Radiol. 2022;148:110156.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2010, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

  33. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of interventions Version 5.1.0. Cochrane Collab 2011, www.cochranehandbook.org.

  34. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

    Article  PubMed  Google Scholar 

  35. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Vetrugno L, Mojoli F, Cortegiani A, Bignami EG, Ippolito M, Orso D, Corradi F, Cammarota G, Mongodi S, Boero E, et al. Italian Society of Anesthesia, Analgesia, Resuscitation, and Intensive Care expert consensus statement on the use of lung ultrasound in critically ill patients with coronavirus Disease 2019 (ITACO). J Anesth Analg Crit Care. 2021;1(1):16.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Song G, Qiao W, Wang X, Yu X. Association of Lung Ultrasound Score with mortality and severity of COVID-19: a Meta-analysis and Trial Sequential Analysis. Int J Infect Dis. 2021;108:603–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Wanguemert Perez AL, Figueira Goncalves JM, Hernandez Perez JM, Ramallo Farina Y, Del Castillo Rodriguez JC. Prognostic value of lung ultrasound and its link with inflammatory biomarkers in patients with SARS-CoV-2 Infection. Respir Med Res. 2021;79:100809.

    CAS  PubMed  Google Scholar 

  39. Rubio-Gracia J, Gimenez-Lopez I, Garces-Horna V, Lopez-Delgado D, Sierra-Monzon JL, Martinez-Lostao L, Josa-Laorden C, Ruiz-Laiglesia F, Perez-Calvo JI, Crespo-Aznarez S et al. Point-of-care lung ultrasound assessment for risk stratification and therapy guiding in COVID-19 patients: a prospective noninterventional study. Eur Respir J 2021, 58(3).

  40. Wang R, Qi B, Zhang X, Meng L, Wu X. Prophetic values of lung ultrasound score on post-extubation distress in patients with acute respiratory distress syndrome. Eur J Med Res. 2022;27(1):27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Eman G, Synn S, Galen B, Shah R, Nauka P, Hope AA, Congdon S, Islam M. Thoracic Ultrasound in COVID-19: Use of Lung and Diaphragm Ultrasound in evaluating Dyspnea in survivors of Acute Respiratory Distress Syndrome from COVID-19 Pneumonia in a Post-ICU clinic. Lung. 2023;201(2):149–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Bouhemad B, Mongodi S, Via G, Rouquette I. Ultrasound for lung monitoring of ventilated patients. Anesthesiology. 2015;122(2):437–47.

    Article  PubMed  Google Scholar 

  43. Baston C, West TE. Lung ultrasound in acute respiratory distress syndrome and beyond. J Thorac Dis. 2016;8(12):E1763–6.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

The study did not receive any specific funding from funding agencies in the public, commercial or non-profit sectors.

Author information

Authors and Affiliations

Authors

Contributions

YQ designed the study. DW and YQ performed literature search, study identification, quality evaluation, data extraction, statistical analysis, and results interpretation. DW drafted the manuscript. DW and YQ revised the manuscript and approved the submission.

Corresponding author

Correspondence to Yun Qi.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, D., Qi, Y. Lung ultrasound score and in-hospital mortality of adults with acute respiratory distress syndrome: a meta-analysis. BMC Pulm Med 24, 62 (2024). https://doi.org/10.1186/s12890-023-02826-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12890-023-02826-5

Keywords